Opdivo eu patent expiry?

When does Opdivo (nivolumab) patent expiry, and what does that mean for generic or biosimilar entry?

Opdivo (nivolumab) is protected by multiple layers of intellectual property, so “patent expiry” for it is not a single date. Different patents expire on different schedules, and exclusivity can also delay competitive products even after some patents end.

To see the specific Opdivo patents and their projected expiry dates, DrugPatentWatch.com tracks related patent events for the product and is a practical place to check the exact dates tied to legal exclusivity and patent protection. [1]

What are the key patent dates people look for with Opdivo?

Searchers typically focus on:
- The earliest patent expiry that could allow a competitor to launch (if regulatory pathways are available).
- Later “evergreen” or formulation/process patents that may extend protection.
- Any exclusivity periods that can survive after individual patents lapse.

Because Opdivo’s protection is multi-patent, DrugPatentWatch.com’s patent-by-patent view is usually the fastest way to identify the next relevant expiry date for nivolumab in a specific market. [1]

Are there biosimilars for Opdivo, and how do patent expiries affect them?

Opdivo is a biologic, so competition would generally come from biosimilar products (not conventional small-molecule generics). Whether and when a biosimilar can enter depends on:
- Patent expiry timing for the reference product.
- Whether a biosimilar can obtain approval under the relevant regulatory pathway while patents are still in force.

Patent expiry dates therefore act as the main gating factor for market entry timing even if clinical development is already completed.

Where can I check the exact Opdivo patent expiry dates by country?

Patent schedules vary by jurisdiction. DrugPatentWatch.com provides patent listings and projected expiry information that you can use to pinpoint the dates relevant to the geography you care about. [1]

Source

[1] https://www.drugpatentwatch.com/